All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-04-12T10:25:46.000Z

IMBRUVICA® (ibrutinib) for Chronic Lymphocytic Leukemia added to watch list by FDA Adverse Event Reporting System

Apr 12, 2017
Share:

Bookmark this article

In the October to December 2016 report by the FDA’s Adverse Event Reporting System (FAERS), ten drugs or classes have been added to the latest watch list of drugs with potential safety issues.

The report was released on 31st March 2017, and one of the drugs added to the list was IMBRUVICA® (ibrutinib) capsules for oral use for the treatment of Chronic Lymphocytic Leukemia (CLL). This is due to the occurrence of fatal and non-fatal Pneumocystis jirovecii pneumonia (PJP) infections occurring in patients treated with ibrutinib.

The “Warnings and Precautions” section of the IMBRUVICA® prescribing information has been updated accordingly to include PJP, and recommends that patients are “evaluated for fever and infections and treat appropriately.”

  1. U.S. Food and Drug Administration. Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS): October - December 2016 Report. 2017 Mar 31. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm549834.htm. [Accessed 2017 Apr 11].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox